Business Context and Reporting Period
Company: Inspire Medical Systems, Inc. (INSR)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: The Company develops and commercializes the Inspire system, a neurostimulation therapy for moderate to severe obstructive sleep apnea (OSA). Operations are conducted as a single segment with revenue derived from sales in the U.S. and select international markets.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 | Q2 2025 | YTD 2026 | YTD 2025 |
|---|---|---|---|---|
| Revenue | $200,581 | $217,086 | $405,164 | $418,403 |
| Gross Profit | $171,459 | $182,414 | $348,371 | $353,022 |
| Gross Margin | 85.5% | 84.0% | 86.0% | 84.4% |
| Operating Loss | $(514) | $(3,316) | $(1,632) | $(4,801) |
| Net Earnings (Loss) | $314 | $(3,592) | $(10,980) | $(600) |
| Diluted EPS | $0.01 | $(0.12) | $(0.38) | $(0.02) |
| Cash & Equivalents (End of Period) | $127,761 | $106,927 | N/A | |
| Total Investments | $287,403 | $299,785 | N/A | |
| Operating Cash Flow (YTD) | $36,077 | $(4,019) | N/A |
Liquidity: As of June 30, 2026, the Company held $127.8 million in cash and cash equivalents and $287.4 million in investments. Total current assets were $608.7 million against $71.2 million in current liabilities.
Material Changes vs. Prior Period
- Revenue Decline: Q2 2026 revenue decreased 7.6% year-over-year to $200.6 million. The decline was driven primarily by U.S. revenue (-9.6%), attributed to coding and reimbursement challenges for the Inspire V system and delays from the WISeR program. International revenue grew 33.6% to $13.3 million.
- Margin Expansion: Gross margin improved to 85.5% in Q2 (from 84.0% in Q2 2025) due to a favorable sales mix shift toward the higher-margin Inspire V system.
- Expense Reduction: Operating expenses decreased 7.4% year-over-year. SG&A expenses dropped 7.7% primarily due to lower stock-based compensation (no accelerated expense in the current period vs. prior year) and reduced marketing spend. R&D expenses decreased 5.8%.
- Profitability: The Company reported a net profit of $0.3 million in Q2 2026, a significant improvement from a net loss of $3.6 million in Q2 2025. However, the YTD 2026 net loss widened to $11.0 million compared to $0.6 million in YTD 2025, largely due to a high effective tax rate (299.2%) driven by stock-based compensation tax shortfalls.
- Cash Flow: Operating cash flow turned positive, providing $36.1 million YTD 2026 compared to a use of $4.0 million in the prior year, driven by improved working capital management.
Guidance, Outlook, and Risks
Strategic Initiatives
On August 3, 2026, the Company announced "Project Horizon," a strategic growth plan to align resources with revenue growth, streamline the organization, and optimize the supply chain. The Company expects to incur $20 million to $25 million in pre-tax restructuring charges, primarily in Q3 and Q4 2026. This is expected to generate approximately $30 million in annualized investment capacity.
Reimbursement and Coding Uncertainty
Significant uncertainty remains regarding Medicare and commercial reimbursement for the Inspire V system. While the AHA recommended CPT code 64999, many payers still reference code 64568. The WISeR program in six pilot states has caused procedural delays. Management anticipates these factors will continue to adversely impact revenue for the remainder of 2026.
Competitive Landscape
The increasing adoption of GLP-1 drugs (e.g., tirzepatide) for obesity and OSA is currently having a short-term adverse impact on revenue as some physicians prescribe these drugs prior to considering Inspire therapy. Management believes long-term eligibility may increase as patients reduce BMI but do not fully resolve OSA.
Legal and Contingencies
- Securities Litigation: An amended securities class action (Indiana PRS Lawsuit) alleges fraud regarding the Inspire V launch and Medicare coding. The case was transferred to Minnesota in May 2026. No loss accrual has been recorded.
- Derivative Lawsuits: Three stockholder derivative lawsuits (Korte, Davis, Ahlberg) have been filed regarding the same subject matter; two have been consolidated and stayed pending the resolution of the class action.
- Government Investigation: The Company is cooperating with a DOJ investigation under the False Claims Act regarding marketing and reimbursement practices. No loss accrual has been recorded.
- Patent Disputes: Ongoing litigation with Nyxoah SA regarding patent infringement claims in the U.S. and the Unified Patent Court.
Investor Verification Checklist
- Reimbursement Resolution: Monitor updates on the finalization of CPT codes for Inspire V and the impact of the WISeR program on procedure volumes.
- Restructuring Execution: Verify the timing and magnitude of "Project Horizon" restructuring charges and the realization of the projected $30 million in annualized investment capacity.
- GLP-1 Impact: Assess the long-term correlation between GLP-1 drug adoption and Inspire therapy eligibility versus short-term revenue cannibalization.
- Legal Exposure: Track the status of the Indiana PRS securities class action and the DOJ False Claims Act investigation for potential financial liabilities.
- Tax Rate Volatility: Review future effective tax rates, as the current period was heavily influenced by discrete stock-based compensation tax shortfalls.